Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Parodontax is a therapeutic toothpaste brand developed by Haleon (formerly GSK Consumer Healthcare) specifically formulated to treat and prevent gingivitis and control dental plaque. The product typically contains sodium fluoride (often at 1400 ppm or 1450 ppm) to promote enamel remineralization and prevent dental caries, alongside a high concentration of sodium bicarbonate (baking soda). The sodium bicarbonate acts as a physical abrasive to disrupt and remove bacterial plaque biofilm, which is the primary cause of gum inflammation and bleeding. In clinical research, Parodontax is frequently utilized as an active comparator to evaluate the efficacy of other gum-health dentifrices in long-term studies measuring plaque indices and gingival health.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Parodontax.